Reactivity characterization of bromoacetyl derivatized polyribosylribitol polysaccharide in Haemophilus influenzae type b for PedvaxHIB® by NMR spectroscopy.


Journal

Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899

Informations de publication

Date de publication:
21 01 2022
Historique:
received: 12 08 2021
revised: 19 10 2021
accepted: 17 11 2021
pubmed: 12 12 2021
medline: 27 1 2022
entrez: 11 12 2021
Statut: ppublish

Résumé

PedvaxHIB® is a highly purified capsular polysaccharide (polyribosylribitol phosphate or PRP) of Haemophilus influenzae type b (Hib) that is covalently linked to an outer membrane protein complex (OMPC) of Neisseria meningitidis pediatric vaccine. This Hib protein conjugate vaccine is very effective in protecting infants from invasive gram-negative bacterium Hib. Before conjugation of PRP to OMPC, PRP is first derivatized with butadiamine and bromoacetyl group which reacts with thiolated OMPC. This report describes an NMR method to analyze the reactivity of bromoacetyl group in derivatized PRP (BrAc-derivatized PRP) toward small molecule thiol group, 2-mercapto imidazole (MI) which is used as a surrogate for thiolated OMPC. Reaction with MI helped identify observable amide protons in BrAc-derivatized PRP according to presence or absence of bromine. Furthermore, the new method can be used to monitor the percent of bromoacetylation during manufacturing and potentially a stability indicating assay for loss of bromine in BrAc-derivatized PRP.

Identifiants

pubmed: 34893342
pii: S0264-410X(21)01506-1
doi: 10.1016/j.vaccine.2021.11.050
pii:
doi:

Substances chimiques

Antibodies, Bacterial 0
Bacterial Outer Membrane Proteins 0
Haemophilus Vaccines 0
Haemophilus influenzae-type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine 0
Polysaccharides, Bacterial 0
Vaccines, Conjugate 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

187-191

Informations de copyright

Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Richard R Rustandi (RR)

Analytical Research Development, Merck & Co., Inc, Kenilworth, NJ, USA. Electronic address: richard_rustandi@merck.com.

Qiuwei Xu (Q)

Analytical Research Development, Merck & Co., Inc, Kenilworth, NJ, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH